Sarepta’s Duchenne gene therapy shows durable efficacy after three years
Sarepta Therapeutics (NASDAQ:SRPT) released long-term data on Monday that bolsters the clinical case for Elevidys, its pioneering gene therapy for Duchenne muscular dystrophy (DMD).























